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Intracerebral transplantation of genetically
engineered cells is a useful method for delivering
recombinant growth factors to the brain. Despite
the clear experimental and therapeutic potential
of this technique, relatively few cell types have
been studied as targets for genetic manipulation
and transplantation. Our interest has been to de-
termine whether primary type I astrocytes, the
normal support cell of the CNS, are suitable for
this purpose.
For these studies, type I astrocytes purified
from newborn rat cerebral cortex were geneti-
cally modified in culture to constitutively express
a mouse/3-NGF transgene, by infection with a
replication-defective retroviral vector as previ-
ously described (Cunningham et al., Brain Res
561: 192-202). Infected astrocytes were found to
release NGF into the culture medium at a rate
that is > 10-fold higher than that of sister cul-
tures of uninfected astrocytes (9.3+_2.9 pg/10s
cells/h vs. <0.8 pg NGF/10 cells/h).
To evaluate the potential of these transgenic
astrocytes to provide trophic support to brain
grafts, their effects on the survival and neuronal
transdifferentiation of intrastriatal adrenal
chromaffin cell co-grafts were evaluated in the
unilateral 6-hydroxydopamine-lesioned rat (an
animal model of Parkinson’s disease). NGF-
producing transgenic astrocytes (AsN.8) were
fluorescently labeled with DiI, mixed 1:1 with
suspensions of postnatal day 12 adrenal chro-
maffi cells (AC; 80,000 cells of each type) and
stereotaxically implanted into the dopamine-
denervated striatum of adult Fischer 344 rats
(n=7). Chromaffin cells grafted alone (AC,
n=4) or with normal astrocytes (AC + As, n=4)
served as controls. Host rats were sacrificed ten
weeks post-grafting. Astroeytes and chromaffin
cells were identified by fluorescence microscopy
and tyrosine hydroxylase immunoreactivity (TH-
IR), respectively. When co-grafted with NGF-
producing transgenic astrocytes, chromaffin cell
survival was enhanced 5-12 fold over controls
(1168+143 vs. 221+128 and 99_+5 TH-IR cells;
AC + AsN.8 vs. Ac and AC + As grafts, respec-
tively, p<0.01). Furthermore, 36% of the chro-
maffi cells co-grafted with the genetically
modified astrocytes displayed a phenotype char-
acteristic of neuronally differentiated sympa-
thetic neurons, i.e., large soma (30-40 m in
diameter), TH-IR neuronal processes and ex-
tensive process elongation. These processes
were also immunoreaetive for the low affinity
NGF receptor, but not for choline acetyltrans-
ferase, indicating that the NGF-producing grafts
do not stimulate aberrant sprouting by host
brain NGF-responsive cholinergic neurons. The
effects of the transgenic astrocytes on chromaf-
fin cell survival and morphology were paralleled
by a 40% reduction in apomorphine-induced
rotation. The results of this study demonstrate
that genetically engineered astrocytes are an
effective vehicle for delivering long-term/3-NGF
trophic support.
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